Listen to the FTX bankruptcy hearing of 6/18/26 re: reduction of the disputed claims reserve

Listen to the FTX bankruptcy hearing of 6/18/26 re: reduction of the disputed claims reserve

Author: Center of Main Interests June 19, 2026 Duration: 52:46

Hey! I'd love to hear your thoughts, send me a voice note.

filed on the FTX bankruptcy docket as docket number 35836 (a PDF file with an embedded mp3 file)


The raw, unfiltered drama of American finance and corporate law unfolds in real time within American court hearing recordings and interviews. This unique podcast, presented by the Center of Main Interests, pulls back the curtain on the pivotal legal battles that shape markets and redefine companies. Instead of summaries or analyst opinions, you are placed directly inside the courtroom, listening to the actual arguments, judicial questions, and witness testimonies from high-stakes bankruptcy proceedings, major investor disputes, and complex restructuring cases. These recordings are complemented by interviews that provide crucial context, helping to decipher the strategies and consequences at play. For professionals in business and investing, or anyone fascinated by the news behind the headlines, this series offers an unparalleled primary source. It’s a direct line to the tense, often unpredictable moments where fortunes are decided and legal precedents are set. Tune into this podcast to hear the unvarnished sound of power, money, and the law colliding, granting a profound understanding of how critical financial outcomes are truly negotiated and determined.
Author: Language: English Episodes: 50

American court hearing recordings and interviews
Podcast Episodes
BioXcel Therapeutics (Nasdaq BTAI) - Listen to the 8/31 court hearing re bankruptcy/asset sale,  #pharma #Teva #IGALMI #agitation #BXCL501 #schizophrenia #bipolardisorder #AI #neuroscience #onkosxcel #dexmedetomidine [not-audio_url] [/not-audio_url]

Duration: 44:21
Hey! I'd love to hear your thoughts, send me a voice note.Per BioXcel's press release:BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva PharmaceuticalsAug 28, 2026 PDF VersionBioXcel Therapeutics intends to…